Mirae Asset Global Investments Co. Ltd. Has $2.68 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Repligen Co. (NASDAQ:RGEN) by 46.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,629 shares of the biotechnology company’s stock after acquiring an additional 5,913 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Repligen were worth $2,679,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Champlain Investment Partners LLC grew its stake in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock valued at $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock valued at $136,395,000 after buying an additional 6,872 shares during the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after buying an additional 36,773 shares in the last quarter. DF Dent & Co. Inc. increased its holdings in Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after buying an additional 139,615 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after acquiring an additional 71,274 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Stock Down 3.6 %

RGEN opened at $156.05 on Monday. The business has a 50 day moving average of $155.37 and a 200-day moving average of $148.93. The stock has a market capitalization of $8.74 billion, a price-to-earnings ratio of -421.75, a P/E/G ratio of 4.54 and a beta of 0.99. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.23 EPS. As a group, sell-side analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have commented on RGEN shares. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. HC Wainwright decreased their price objective on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $184.73.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.